Titre :

The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the European Scleroderma Trial and Research Database.

Auteur(s) :

Lepri, G. [Auteur]
Università degli Studi di Firenze = University of Florence = Université de Florence [UniFI]
Bruni, C. [Auteur]
Tofani, L. [Auteur]
Moggi-Pignone, A. [Auteur]
Orlandi, M. [Auteur]
Tomassetti, S. [Auteur]
Hughes, M. [Auteur]
Del Galdo, F. [Auteur]
Irace, R. [Auteur]
Distler, O. [Auteur]
Riccieri, V. [Auteur]
Allanore, Y. [Auteur]
Gheorghiu, A. M. [Auteur]
Siegert, E. [Auteur]
De Vries-Bouwstra, J. [Auteur]
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Tikly, M. [Auteur]
Damjanov, N. [Auteur]
Spertini, F. [Auteur]
Mouthon, L. [Auteur]
Hoffmann-Vold, A. M. [Auteur]
Gabrielli, A. [Auteur]
Guiducci, S. [Auteur]
Matucci-Cerinic, M. [Auteur]
Furst, D. [Auteur]
Bellando-Randone, S. [Auteur]
Eustar, C. O. L. L. A. B. O. R. A. T. O. R. S. [Auteur]

Titre de la revue :

Diagnostics (Basel)

Nom court de la revue :

Diagnostics (Basel)

Numéro :

14

Pagination :

295

Éditeur :

MDPI

Date de publication :

2024-02-12

ISSN :

2075-4418

Mot(s)-clé(s) en anglais :

computed tomography (CT)
interstitial lung disease
scleroderma
pulmonary function test

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background and Objectives: In SSc, ILD is a major cause of morbidity and mortality. We aimed to investigate the performance of DLCO (diffusing capacity of lung carbon monoxide) and FVC (forced vital capacity) delta change ...
Lire la suite >Background and Objectives: In SSc, ILD is a major cause of morbidity and mortality. We aimed to investigate the performance of DLCO (diffusing capacity of lung carbon monoxide) and FVC (forced vital capacity) delta change (Δ) and baseline values in predicting the development of SSc-ILD. Methods: Longitudinal data of DLCO, FVC, and ILD on the HRCT of SSc patients from the EUSTAR database were evaluated at baseline (t0) and after 12 (±4) (t1) and 24 (±4) (t2) months. Results: 474/17805 patients were eligible for the study (403 females); 46 (9.7%) developed ILD at t2. Positivity for anti-topoisomerase antibodies (117 patients) showed an association with ILD development at t2 (p = 0.0031). Neither the mean t0 to t1 change (Δ) of DLCO nor the mean t0 to t1 FVCΔ predicted the appearance of ILD at t2. Investigating the possible role of baseline DLCO and FVC values in predicting ILD appearance after 24 (±4) months, we observed a moderate predictive capability of t0 DLCO < 80%, stronger than that of FVC < 80%. Conclusions: We suggest that an impaired baseline DLCO may be predictive of the appearance of ILD after 2 years of follow-up. This result advances the hypothesis that a reduction in gas exchange may be considered an early sign of lung involvement. However, further rigorous studies are warranted to understand the predictive role of DLCO evaluation in the course of SSc.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-05-06T21:48:56Z
2024-09-04T07:45:35Z